Transcatheter Tricuspid Repair More Than Doubles Survival Free of Heart Failure at Three Years

Tricuspid regurgitation has long been the forgotten valve disease. Unlike aortic stenosis, where the calcific jet and the gradient on echo make the diagnosis viscerally obvious, severe TR often hides behind the dominant left-sided pathology that caused it. By the time patients are symptomatic with TR — swollen legs, fatigue, exercise intolerance — the right ventricle is typically dilated and dysfunctional, surgical repair carries high operative mortality, and the temptation to treat medically and accept the trajectory is real. TRIC-I-HF changes that calculus. The trial, published August 30, 2026 in the New England Journal of Medicine and presented at ESC Congress in Munich, is the largest randomized study of transcatheter tricuspid repair to date, and its results are not subtle.[1]

Three hundred sixty patients with symptomatic severe TR and elevated risk for surgical repair were randomized 2:1 to transcatheter edge-to-edge repair (TEER) plus optimal medical therapy versus medical therapy alone. The primary endpoints were two-tier: a 1-year hierarchical composite measured by win ratio, and a 3-year freedom from death or heart failure hospitalization. At 1 year, the win ratio was 2.42 (95% CI 1.76–3.33), meaning patients in the repair group were more than twice as likely to have a favorable outcome across the full hierarchy of endpoints. At 3 years, the gap widened further: 52.4% of repair patients were alive and free from HF hospitalization, compared with 21.0% in the medical therapy group.[1]

Those are large absolute differences in a patient population where the natural history is grim. TR, when symptomatic and severe, drives progressive right ventricular remodeling, hepatic congestion, and ultimately multiorgan dysfunction. Medical therapy with diuretics ameliorates congestion but does nothing to arrest the underlying valvular pathology. The TRIC-I-HF result demonstrates that correcting the leak — even with a catheter-based procedure in patients deemed too high-risk for surgery — can dramatically alter the trajectory.

Clinical Context

The TRILUMINATE Pivotal trial (2023) established transcatheter TR repair for symptom benefit and quality of life, but was not powered for clinical outcomes like mortality or hospitalization.[2] TRIC-I-HF was designed explicitly to answer the harder question: does repair change the natural history of the disease, not just the symptom burden? It does. The magnitude of effect on 3-year freedom from death or HF hospitalization — a roughly 31 percentage-point absolute difference — is clinically compelling and will almost certainly reshape guideline recommendations. Current ACC/AHA guidelines give transcatheter TR repair a Class IIb recommendation; TRIC-I-HF provides the evidence base for upgrading it substantially.[3]

The trial enrolled a population that resembles real-world severe TR patients: median age in the mid-70s, predominantly atrial fibrillation driving functional TR, most with some degree of right ventricular dysfunction. These are not straightforward surgical candidates. The procedural system used was a TEER device, the same conceptual approach as MitraClip in the mitral position. The procedure grasps and coapts the tricuspid leaflets under echo and fluoroscopic guidance, reducing regurgitation severity. TR grade reduction to moderate or less was achieved in the majority of repair patients.

Why It Matters Clinically

The TRIC-I-HF findings also matter for how TR patients are referred. Historically, cardiologists have managed TR medically while optimizing the co-existing HF and AF, referring to surgery only when patients deteriorated further — at which point surgical risk had often risen further too. A randomized trial showing a win ratio of 2.42 at 1 year and a 52.4% vs 21.0% 3-year freedom from hard outcomes makes the case for earlier intervention, before RV dysfunction becomes irreversible. This is the same lesson that reshaped mitral valve management over the past decade: the window for effective structural intervention closes as the myocardium remodels.

For structural heart programs, TRIC-I-HF will accelerate the development of tricuspid TEER as a standard-of-care procedure. The learning curve for TEER in the tricuspid position is steeper than for the mitral, and volume-outcome relationships are likely to be important. Referral to experienced centers will matter. But the evidence base for the procedure is now substantially stronger than it was 30 days ago.

Limitations

Open-label design means physicians and patients knew which group they were in, potentially influencing HF hospitalization rates. The 2:1 randomization (more to repair) was practical but reduces control group precision. TR etiology was predominantly functional/secondary; primary (leaflet) TR is a different population. Long-term RV function data beyond 3 years are needed. The specific TEER device used may not generalize to all transcatheter TR platforms now under development.